Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MCRA Helps Small Spine Companies

This article was originally published in Start Up

Executive Summary

Clinical trials strategies, particularly in the medical device industry, can confer an important competitive advantage to a company-or present a stumbling block that costs time, money, and markets. This is particularly true in orthopedics, where development lead times stretch into years. In hip, knee, and spine surgery, companies with new technologies can enjoy first-mover advantages that let them dominate markets for five, even ten years, but market delays can undercut such advantages. That's why Viscogliosi Brothers LLC, a venture capital firm/merchant bank focused exclusively on the musculoskeletal industries, recently formed Musculoskeletal Clinical Regulatory Advisors LLC (MCRA), a firm that aims to help orthopedics start-ups develop and execute clinical research strategies.

You may also be interested in...



Spine-Bending Market

Today, the market for spine surgery is growing by more than 20% annually based on fusion technologies alone, despite the fact that those technologies are decades old and flawed. However, a heightened awareness of the clinical drawbacks of fusion is fueling prolific company creation in a new spine motion preservation segment of the industry. Some 118 start-ups in spine are dotting the landscape. Many hope to offer new devices that address spinal joint reconstruction; artificial discs, disc nuclei, annulus repair, facet joint replacement, and dynamic or flexible stabilization of the spine.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel